Corrects paragraph 3 in May 28 story to say "eye drop", not "liquid medication"
May 28 (Reuters) - Eye-care drugmaker Alcon ALCC.S said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).
Spun off from Novartis NOVN.S in 2019, Alcon is betting on new product launches to accelerate sales growth in the second half of 2025 and beyond.
The approval was based on late-stage studies in which the eye drop, Tryptyr, demonstrated natural tear production as early as day one.
The company said Tryptyr stimulates corneal sensory nerves to quickly increase natural tear production.
DED is a condition in which the eyes either do not produce enough tears or produce poor-quality tears, leading to discomfort and potentially affecting vision.
The company said about 38 million individuals in the United States suffer from DED, yet fewer than 10% of diagnosed patients are being treated with a prescription product.
Alcon, which produces contact lenses, dry eye drops, gels and other related products, expects to launch Tryptyr in the United States during the third quarter of 2025, with plans to introduce the treatment in other markets later.
Other FDA-approved treatments for DED include Alcon's Eysuvis and Bausch + Lomb's BLCO.TO Xiidra.
Last month, however, the FDA declined to approve Aldeyra Therapeutics' ALDX.O treatment for DED.
(Reporting by Puyaan Singh in Bengaluru; Editing by Mohammed Safi Shamsi)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。